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from different species. We show that replication competent XMRV infects various human cell types,
including hematopoietic cell lines and prostate stromal ﬁbroblasts. XMRV–LTR activity is signiﬁcantly higher
in the prostate cancer cell line LNCaP and in prostate stromal ﬁbroblasts, compared to other cell types tested
and could be one factor contributing to efﬁcient viral spread in prostate tissue.ramson Family Cancer Center,
phia, PA 19104, USA.
ll rights reserved.© 2009 Elsevier Inc. All rights reserved.Introduction
Recently, a new gammaretrovirus associated with a rare form of
familial human prostate cancer, which was named XMRV due to its
homology to xenotropic murine leukemia viruses (X-MLV), was
discovered (Urisman et al., 2006). The virus was detected almost
exclusively in samples isolated from patients that are homozygous for
a speciﬁc RNASEL allele, demonstrating a strong link between XMRV
infectivity and reduced RNase L activity. A second study in North
America conﬁrmed a high incidence of XMRV in prostrate cancer
samples, which was independent of the RNASEL allele (Schlaberg et
al., 2009). In studies conducted in Northern Europe, however, the
virus was rarely detected in unselected prostate cancer samples, thus
suggesting differences in the worldwide distribution of XMRV
(Fischer et al., 2008; Hohn et al., 2009). Two recent studies have
provided evidence with regard to the putative transmission routes of
XMRV; Hong and colleagues propose that XMRV might be sexually
transmitted (Hong et al., 2009) and a recent ﬁnding by Lombardi and
coworkers raises the possibility of XMRV being a blood borne
pathogen (Lombardi et al., 2009). In this latter study, XMRV-speciﬁc
sequences were detected in up to 70% of peripheral blood monocytes
(PBMCs) from patients with chronic fatigue syndrome (CFS).Immunohistochemistry studies have conﬁrmed the presence of
XMRV in prostrate samples, but FISH-positive staining for XMRV was
restricted to only a very few ﬁbroblasts (∼1%) of the prostate stroma
(Urisman et al., 2006), indicating a tight restriction of virus spread in
vivo. In a more recent study in which XMRV-speciﬁc antiserum was
used, XMRV protein expression was detected in epithelial cells of
unselected prostate cancer tissues (Schlaberg et al., 2009), suggesting
a more direct involvement of XMRV in prostate cancer tumorigenesis.
Together with the ﬁnding that XMRV sequences are also detected in
the prostate epithelium cell line 22Rv1 (Knouf et al., 2009), these
studies indicate that XMRV infection might not be limited to prostate
stromal ﬁbroblasts in vivo.
The XMRV provirus is not endogenous to the human genome and
there are no similarities to human endogenous retroviral sequences,
suggesting that XMRV is transmitted by exogenous infection. Due to
high nucleotide identity (95%) with several full-length Mus musculus
endogenous and exogenous proviruses, it is likely that themouse is the
original source of the virus–but it is probably not the current reservoir
for infections. As XMRV is the ﬁrst example of an extant human
exogenous gammaretrovirus, its existence raises many questions with
regard to the etiological link between retroviral infection and cancer,
but also to the nature of the virus reservoir, route of transmission and
the integrity of cellular barriers that have evolved to control retroviral
infections. To address the latter, it is necessary to understand the
cellular and retroviral factors that modulate XMRV infection.
An importantmodulator of virus host range and tissue speciﬁcity is
the interaction of the cellular receptor and the retroviral Env. Based on
Table 1
Host range analysis of pseudotyped murine leukemia viruses.
Cell linea
Titers (GFP iU × 105/ml) of Env pseudotyped MLVb
XMRV Xeno 10A1 Eco
TE 671 9.5 13 6.2 ndc
HeLa 5.6 4.8 4.0 ndc
Jijoye 0.4 0.09 0.4 ndc
DU145 2.9 3.0 1.8 ndc
LNCaP 1.2 3.0 2.2 ndc
293T 2.4 2.8 0.95 ndc
REH 0.08 0.02 0.08 ndc
HL60 0.5 0.25 0.65 ndc
PrSc 1.9 4.2 0.3 ndc
HUVECs 0.27 ndc
NIH3T3 nd nd 2.3 6.3
a Cell lines used in infection experiments are of human origin with exception of the
mouse cell line NIH3T3.
b Cells were infected with Env pseudotyped SF91-GFP retroviral vector with an MOI
of 4. GFP iU/ml was determined by FACS analyses. Titers were calculated as the
arithmetic mean of three independent experiments. Boxed values label statistically
signiﬁcant differences in titers between the two xenotropic pseudotyped viruses. PrSc
stands for prostatic stromal cells.
c nd, not detectable.
Fig. 1. XMRV env pseudotyped particles display xenotropic host range. Human cell lines
(dark gray bars), feral mouse cell line SC1 (gray bar), inbred mouse cells NIH3T3,
hamster cells A23 and BHK, mink cells CCL64, monkey cells Cos7, doc cell line D17, cells
of bovine origin (MDBK) and porcine cells PK15 were infected with XMRV Env
pseudotyped SF91-GFP retroviral supernatant (MOI 8). GFP-positive cells were
measured 72 h after transfection using FACS analysis. Cell lines from species other
than human and mouse are illustrated as white bars. The experiment was replicated
four times using triplicates.
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SU domain (87% for VRA and 78% for VRB) with different xenotropic
MLVs (e.g., NZB-9-1, NFS-Th-1 und DG75) (Urisman et al., 2006), the
cellular receptor for XMRV was predicted to be XPR1, a multi-
membrane-spanning molecule identiﬁed as the receptor for xenotro-
pic and polytropic MLVs (Battini et al., 1999; Tailor et al., 1999; Yang
et al., 1999). This prediction was conﬁrmed by overexpression of the
human XPR1 receptor protein in non-permissive NIH3T3 and CHO
cells which renders them permissive for XMRV infection (Dong et al.,
2007). However, studies have not been performed to compare the
infection efﬁciencies of different cell types when mediated by either
xenotropic or XMRV env proteins. Furthermore, although RNA
analyses has indicated a ubiquitous expression of XPR1 in human
tissue (Battini et al., 1999; Tailor et al., 1999), the localization of XPR1
within the plasma membrane of different cell types has not been
previously addressed.
In addition to the envelope protein, the long terminal repeat (LTR)
region is the second major determinant of retroviral tropism.
Enhancer elements that speciﬁcally interact with transcription factors
are localized within the promoter region, in particular within the U3
region. The LTR of XMRV is 535 nucleotides long and has the highest
nucleotide identity (96%) with LTRs from xenotropic MLVs (Fig. 5A)
(Urisman et al., 2006). However, single nucleotide substitutions and
an insertion of AG dinucleotide immediately downstream from the
TATA box have been described for XMRV (Urisman et al., 2006).
This study was initiated to determine whether the XMRV tissue
distribution in vivo was related to cell type-speciﬁc receptor
expression and/or usage, or due to the expression of cellular factors
essential for LTR activity. Our study documents that XMRV restriction
in vivo can only be partially explained by the two major determinants
of retroviral tropism: receptor distribution and LTR function. XMRV
env pseudotyped particles, as well as replication competent XMRV,
show a typical xenotropic host range infecting feral mouse cells, all
types of human cells tested and several non-rodent species. XMRV
binding experiments indicate that although XPR1 is ubiquitously
expressed in all cell types analyzed, its functional localization on the
plasma membrane varies between different cell types. Furthermore,
XMRV–LTR activity is signiﬁcantly higher in primary stromal
ﬁbroblasts isolated from prostate tissue or the prostate cancer cell
line LNCaP, as compared to other cell types. The increased promoter
activity in the prostate compartment was also observed for related
MLV LTRs and is therefore not unique to XMRV LTR.
Results
Analysis of the cell type speciﬁcity of the XMRV Env pseudotypes
The restricted infection pattern of XMRV in stromal ﬁbroblast
observed in patient samples in vivo is in striking contrast to earlier in
vitro data demonstrating that a wide range of cell types are infectable
by X-MLVs. To test the host range of XMRV, cell lines of different tissue
origins were tested for infection with XMRV Env pseudotyped MLV
particles containing a retroviral vector expressing GFP. As controls,
infection efﬁciencies of Env-pseudotypes representing different
gammaretrovirus receptor groups were compared. These include
the xenotropic NZB-MLV, which uses XPR1 as a receptor and the
recombinant 10A1-MLV, which can use both phosphate transporter
proteins PiT1 and PiT2 as putative receptor molecules (Battini et al.,
1999; Miller and Chen, 1996). Additionally, ecotropic env pseudo-
typed virus particles (using the amino acid transporter CAT-1 on
mouse cells) were included as negative controls (Table 1).
Cell type speciﬁcity was determined on a number of human cell
lines, including the LNCaP and DU145 prostate cancer cells, primary
cells from human umbilical vein endothelial cells (HUVEC) and
primary prostate stromal ﬁbroblasts (PrSc) (Table 1). The PrSc cells
were of particular interest due to the restricted infection pattern ofXMRV observed in vivo. Strikingly, XMRV efﬁciently infects all human
cells lines and primary cells tested. Infection titers of XMRV Env
pseudotypes on stromal cells, whose identity was conﬁrmed by
immunohistochemical staining (cytokeratin negative and vimentin
positive; data not shown), were indistinguishable from other human
cell lines, demonstrating that PrSc cells are not preferentially targeted
by XMRV Env–receptor interactions as measured ex vivo.
Although, all the different human cell types used here were
receptive to both XMRV and X-MLV pseudotype infections, relative
infection efﬁciencies varied between cell lines, but also between virus
types (Table 1). For instance, Jijoye and REHB-cells and primaryHUVEC
endothelial cells were more efﬁciently infected with XMRV Env
pseudotypes, with approximately a ﬁve-fold higher titer than observed
with X-MLV pseudotypes (Table 1, boxed), whereas a two-fold lower
titer was observed for XMRV on LNCaP and PrSc cells (Table 1).
We next asked if the XMRV Env can also mediate infection of cell
lines from other animal types (Fig. 1). For this study, a wide spectrum
of cells from different species (human, hamster, mink, pig, cow and
monkey) was subjected to Env pseudotyped infection assays.
25K. Stieler et al. / Virology 399 (2010) 23–30Consistent with the xenotropic interference group, pig PK15 cells, dog
D17 cells, monkey COS7 and mink CCL64 cells were highly permissive
for virus infection. Bovine MDBK cells were also susceptible to XMRV
Env pseudotyped particles, although to a lesser extent, whereas
hamster cell lines BHK21 and A23 were restricted to XMRV Env
infection. In general, we found that all human cell lines tested were
susceptible to XMRV Env infections, yielding higher infectious titer
units as compared to cell lines from other species.
Transient expression of hXPR1 conferred infectivity to the non-
permissive inbred mouse cell line NIH3T3 cells, although to lesser
extent as compared to human cell lines (Fig. 1). Similar differences
were observed when human XPR1 was transiently expressed in non-
permissive CHO cells and A23 cells (data not shown), as well as in
experiments using stable transfection of the XPR1 receptor in NIH3T3
cells (data not shown).
Infection and viral spread of replication competent XMRV
To test the ability of XMRV to productively infect human cells, a
full-length proviral clone was constructed using two overlapping
XMRV fragments from a patient VP62 to generate XMRV infectious
particles (Dong et al., 2007; Urisman et al., 2006). After transfection of
proviral DNA into various human cell lines, as well as primary stromal
ﬁbroblasts isolated from prostate tissue, supernatant was harvested at
different time points and used to infect the indicator cell line LNCaP.
Infection of LNCaP cells was monitored using a highly sensitive PCR
method. Surprisingly, only in the case of 293T cells and the prostate
cancer cell line LNCaP, which shows low RNase L activity, could
production of XMRV be detected (Table 2). No virus release could be
detected from TE671 cells, HeLa cells, the prostate cancer cell line
DU145 or the human epithelial cell line A549.
Replication of XMRV in human cell lines was further investigated
by infecting cells with XMRV containing supernatant from LNCaP cells
chronically infected with XMRV. Infected cells were monitored for
XMRV replication over a period of 21d by isolating RNA after 5d, 8d,
12d and 21d past infection followed by real-time RT-PCR speciﬁc for
XMRV. Replication of XMRV could be observed in HeLa cells, the
prostate cancer cell lines DU145 and LNCaP, epithelial lung cell line
A549, TE671 cells, and primary stromal ﬁbroblasts isolated from
prostate tissue (Table 2). The levels of XMRV transcripts were
consistently lower in 293T cells, suggesting less efﬁcient XMRV
replication in these cells. Despite stable detection of XMRV transcripts
over the 21-day period in all cell lines, viral particles could only be
detected in cell supernatants from LNCaP, PrSc, and 293T cells by
Western blotting (Table 2).
XMRV infectious pseudotypes produced from chronically
infected 293YFP cells (carrying a SF91-YFP retroviral vector) couldTable 2
XMRV producer cell lines and XMRV replication in human cell lines.
Cell
line
RT-PCR from different cell
lines
Viral particles
releasea
PCR from indicator
cellsb
TE 671 + − +
HeLa + − +
293T (+) (+) (+)
Du145 + − +
LNCaP + + +
A549 + − +
PrSc + + +
Cells were transfected with XMRV proviral DNA. Supernatant was collected every 24
h from the indicated cell lines for a time period of 21 days, ﬁltered and subsequently
applied to the indicator cell line LNCaP, which were then analyzed by nested PCR for
the presence of viral DNA 72 h after infection. Viral particles (released from the cells
transfected with proviral DNA) concentrated by ultracentrifugation were analyzed by
Western blotting for the expression of gag-CA p30. + denotes release of viral
particles measured by immunoblottinga or XMRV-speciﬁc sequences in the indicator
cell line LNCaPb.efﬁciently infect various human cell lines, as well as primary cells,
as determined by FACS analysis (Table 3). 293T and TE671 cells
showed the highest levels of XMRV infectivity, while infection titers
on HUVEC cells were reduced by a factor of ﬁve and by a factor of
10 on primary stromal ﬁbroblast and human HL60 promyeloblasts.
The observed reduction in viral infection titers is inline with
reduced proliferation rates of PrSc, HUVEC's and HL60 cells
compared to TE671 and 293T cells.XPR1 is an ubiquitously expressed plasma membrane protein
To determine whether differences in infection efﬁciencies
reﬂected receptor expression levels, immunoblot analysis was
performed on all cell lines tested. Strikingly, no strict correlation
between XPR1 expression levels and infection efﬁciency of XMRV-
pseudotypes was observed (Fig. 2 and Table 1). In a second
approach to assess XPR1 expression levels, we used a chimeric
antibody (XMRVRBDrFc) encompassing the receptor binding domain
(RBD) and the proline rich region (PRR) of XMRV Env, fused to the
constant fragment of a rabbit immunoglobulin rFc. Earlier work has
shown that expression of N-terminal truncated RBD in cells produce
soluble proteins that fold autonomously, bind their receptor, and
interfere with infection (Barnett et al., 2003; Battini et al., 1995;
Battini et al., 1996; Fass et al., 1997; Heard and Danos, 1991; Kim et
al., 2004; Lavanya et al., 2008). After conﬁrming expression of
XMRVRBDrFc protein by Western blot analysis (data not shown), the
functionality was tested by infection–interference experiments
(Fig. 3A). Infection of TE 671 and SC1 cells with XMRV Env
pseudotyped particles was efﬁciently blocked (37% and 26% of
initial levels, respectively) by the addition of XMRVRBDrFc contain-
ing supernatant (Fig. 3A). In contrast, only marginal reduction in
infectivity was observed when culture medium from mock-
transfected cells was used. Furthermore, addition of XMRVRBDrFc
had only minor effects on 10A1 infection (80% residual infection in
TE 671 cells and 85% in SC1 cells), demonstrating the speciﬁcity of
inhibition of XMRVRBDrFc for XMRV infections.
To further verify that the XMRV-RBD domain actually recog-
nized XPR1, culture medium containing XMRVRBDrFc was used in
cell binding experiments with non-permissive and permissive cells,
as well as originally non permissive NIH3T3 cells transiently
expressing the human variant of Xpr1 (Figs. 3B and C). Binding of
the XMRV Env-derived RBD to the target cell surface was
quantiﬁed using an anti rabbit-FITC antibody and subsequent
FACS analysis (Fig. 3C). This analysis gave consistent results to
that observed by Western blot analysis (compare Fig. 2), but also
conﬁrmed that the receptor was located in the plasma membrane
and thus assessable to XMRV binding. These studies thus show
that XMRVRBDrFc protein can be used as an alternative to XPR1
antisera to study receptor localization and functionality. However,
different binding efﬁciencies between XMRVRBDrFc and Xpr1
orthologues have not been analyzed and may account for observed
variability between different species; a problem also inherent to
different antisera.Table 3
Infection of human cells with replication competent XMRV.
Replication
competent
virus
YFP iU × 104/ml
LNCaP 293T PrSc HUVECs HL60 Z
XMRV 1.0 4.0 0.1 0.28 0.12
Cells were infected with an MOI of 4 (determined on TE671 cells) using supernatant
from 293YFP cells transfected with a replication competent XMRV provirus and
cultured for 2 months. YFP iU/ml was determined by FACS analyses. Titers were
calculated as the arithmetic mean of three independent experiments performed in
triplicates.
Fig. 2. XPR1 expression levels in cell lines. Immunoblot analysis of total protein extracts
from various human cell lines. 25 μg of total protein per lane was separated on a 10%
SDS gel, probed with anti-human XPR1 antibody (A) and reprobed to ensure equal
protein amounts using an anti-β tubulin antibody (B).
Fig. 3. (A) XMRVRBDrFc efﬁciently blocks binding. TE 671 cells or feral mouse cells SC1
were preincubated with culture medium containing XMRVRBDrFc or control medium
and subsequently infected with XMRV env, Xeno env or 10A1 env pseudotyped MLVs.
Infectivity was measured by FACS analysis 3 days after infection. Infection of cells is
indicated as relative infection levels of one representative experiment out of four. (B)
Env-binding assays using XMRVRBDrFc fusion proteins. Binding assays were performed
using XMRV permissive human cell line HeLa, the non-permissive mouse cell line
NIH3T3 and NIH3T3 cells transiently transfected with the human XPR1 variant. Cells
were incubated with culture medium from cells expressing XMRVRBDrFc (empty
histograms) or with culture medium from Mock transfected cells (gray-ﬁlled
histograms) and analyzed by FACS after incubation with anti-rabbit FITC IgG. (C) Δ
mean ﬂuorescence intensity values (ΔMFI) were used to quantify binding of XMRV-
RBDrFc to different human cell lines, mouse cell line NIH3T3 and the hamster cell line
BHK21.
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Our experiments indicate that receptor distribution can not
explain the observed in vivo restriction of XMRV infection. In addition,
we found that only a few cell lines support efﬁcient XMRV spread.
Therefore, we sought to explore whether XMRV–LTR activity may be a
factor for the observed results with regard to XMRV infection in vivo
and in vitro. The LTR encompassing the complete U5-R-U3 region was
fused to ﬁreﬂy luciferase gene (Fig. 4A), transiently transfected in
different human and mouse cell lines, analyzed for transcription and
normalized using a renilla luciferase expression construct (Fig. 4A). In
each cell line, the relative activity of XMRV LTR was determined with
respect to Herpes simplex virus TK promoter driven luciferase
activity. 293T and HeLa cells were chosen because they generally
support high levels of expression from a variety of different
promoters. Additionally, prostrate cell lines, LNCaP and DU145 and
primary stromal ﬁbroblasts established from two different patients
were analyzed for promoter activity. With the exception of 293T cells,
all cell lines tested showed robust XMRV–LTR activity (Fig. 4B).
Interestingly, transcriptional activity was the highest in cell lines that
supported XMRV spreading: the prostate cancer cell line LNCaP and
primary prostatic stromal ﬁbroblasts. LTR activity was signiﬁcantly
reduced in HeLa cells, as well as in the prostate cancer cell line DU145.
To our surprise, 293T cells which could be chronically infected with
XMRV demonstrated only marginal XMRV–LTR transcriptional activ-
ity, but which may explain the relatively low levels of XMRV
transcripts observed in these cells after infection.
Comparison of XMRV–LTR activity to other full-length retroviral LTRs
In addition to testing the XMRV LTR in the luciferase transcription
assays, we also tested two full-length MLV LTRs that are distinct to
XMRV and typically used as enhancer/promoter units in retroviral
vectors, namely the LTRs fromMoloney (Mo)-MLV, and Friend spleen
focus forming virus (SFFV). A phylogenetic tree of the U3-R LTR region
of all LTRs used in this study and, additionally, the xenotropic NZB-
MLV LTR is shown in Fig. 5A. Both LTR transcription plasmids were
compared to the promoter activity of XMRV LTR in 293T, HeLa, LNCaP
and stromal ﬁbroblasts (Fig. 5B). We did not see signiﬁcant
differences with regard to cell speciﬁc transcriptional activity of the
LTR regions tested, with the exception of 293T cells. XMRV LTR is the
only promoter in our experimental setting possessing only marginal
transcription activity in 293T cells; MoMLV LTR and SFFV LTR
displayed robust luciferase expression. Furthermore, we found that
increased transcriptional activity in prostate cell line LNCaP and
prostate stromal ﬁbroblasts is not unique to XMRV LTR; all three LTR
constructs possess increased transcriptional activity in prostate
stromal ﬁbroblasts as well as in the prostate cancer cell line LNCaP.
Discussion
Recently, the ﬁrst human infection with a xenotropic murine
leukaemia virus has been reported; XMRV was identiﬁed in tissue
Fig. 4. (A) LTR-luc reporter construct and control reporter constructs. pGL4-TK was
used as positive control and pBIND for normalization purposes. (B) XMRV–LTR activity
in human and mouse cell lines. U3-R-U5 LTR luciferase activity in human cell lines 293T
(light gray bar), HeLa (dark gray bar), the prostate cancer cell lines LNCaP and Du145
(white bars), in human primary stromal ﬁbroblast isolated from two different patients
(black bars) as well as in feral mouse cell line SC1 and in mus dunni cells (dotted bars)
was determined 24 h after transfection. The experiment was four times repeated using
triplicates.
Fig. 5. (A) Phylogenetic comparison of U3-R LTR region of retroviruses. Phylogenetic
tree based on U3-R nucleotide sequences from NZB gi|332081, XMRV gi|88765817,
FrMLV gi|9626096, SFFV gi|9626955 and MoMLV gi|2801468. Multiple sequence
alignment of the U3-R sequence were constructed with CLUSTALX and used to generate
a neighbor-joining tree using the software CLC sequence viewer. Bootstrap values
(n=1000 trials) are shown as percentages. (B) XMRV–LTR activity shows minor
differences to SFFV-LTR and MoMCF-LTR. The relative luciferase activity of U3-R-U5
reporter constructs of XMRV, SFFV and MoMCF was compared to each other in the cell
lines indicated.
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(Urisman et al., 2006). In addition to HIV and HTLV, which belong to
the lenti- and δ-retrovirus genera, respectively, XMRV is the third
class of exogenous infectious retroviruses found to replicate in
humans. Two recent reports indicate that XMRV infection might
have a larger impact on human diseases: XMRV protein expression
was described predominantly in epithelial cells of the prostate in up to
25% of all prostate cancers analyzed (Schlaberg et al., 2009) and
XMRV-speciﬁc sequences were identiﬁed in 67% of PBMCs of patients
with CFS (Lombardi et al., 2009). These observations, which still need
conﬁrmation by other groups, evoke questions about the tissue
tropism of the virus and the cellular factors that govern infection.
Therefore, knowledge of the host range of XMRV and the cell types
susceptible to infection is necessary to determine the potential
reservoirs of the virus. In this study we characterized the Env–
receptor interactions that dictate XMRV infection in vitro, providing
information with regard to cell and tissue tropism of XMRV and its
potential host range. Additionally, we present data regarding
expression levels and plasma membrane localization of the XMRV
receptor, XPR1. Furthermore, we demonstrate that XMRV promoter
activity signiﬁcantly varies in different cell lines, with the prostate
cancer cell line LNCaP and primary prostate stromal ﬁbroblasts
yielding highest promoter activity.
By infecting cell lines from various species with XMRV Env
pseudotyped particles, we showed that XMRV indeed possesses the
expected “xenotropic” host range (Urisman et al., 2006). XMRV Env
pseudotyped particles are unable to infect cells derived from
laboratory mouse strains or from hamsters, but can infect cells from
outbred feral mice, as well as mink, dog, pig cow and monkey–
although with signiﬁcant lower efﬁciency compared to human cells.
Our results are supported by recently published data describing six
distinct host range variants among naturally occurring xenotropic/
polytropic MLVwith XMRV and AKR6MLV (xenotropic MLV) deﬁningone distinct host range type (Yan et al., 2009). The efﬁcient infection
of human cells could be attributed to efﬁcient binding to the human
XPR1 variant, as shown by infection and binding assays using XMRV
non-permissive cells NIH3T3, genetically engineered to express the
human XPR1 variant. It is important to note that the ability of XMRV
Env to direct infection to other animals means that the virus reservoir
for XMRV infections may not be limited to mouse or man.
In light of the fact that XMRV uses XPR1 as a receptor and due to
the broad tissue expression of XPR1 (Battini et al., 1999), it would be
expected that XMRV would be able to infect a wide spectrum of
tissues–in contrast to its limited cell-type distribution observed in
prostrate tumors. Indeed, we could show that XMRV Env, like other
xenotropic Env, is able to mediate infection of many human cell types,
including lymphocytes, primary cells of epithelial origin and cells of
prostatic stromal origin. Our observations are in concordance with
data from Hong and colleagues who demonstrated that prostatic
stromal cells, prostatic epithelial cells and cells from lymphoid origin
can be efﬁciently infected with replication competent XMRV (Hong et
al., 2009). Generally, there was no statistically signiﬁcant difference
between the infection efﬁciencies of XMRV and X-MLV Env pseudo-
typed particles on different human cell types, although XMRV
infection frequencies were ﬁve-fold higher on B lymphocytes (Jijoye
and REH) and HUVEC cells, but lower by a factor of two on primary
prostate ﬁbroblasts and established LNCaP cells. The reason for the
observed difference is unclear, but they demonstrate that the XMRV
Env is not functionally equivalent to other X-MLV.
Furthermore we show that the variations in virus titers of
XMRV–Env pseudotypes on various human cells, with similar
proliferation rates, could not be solely explained by differences in
receptor expression. Using different techniques that detect XPR1 at
either the protein level (Western blot analysis, immunoﬂuores-
cence, FACS analysis) or RNA level (RT-PCR), a strict correlation
between the amount of receptor being expressed and infectivity of
the cells could not be observed, indicating that other cellular factors
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been suggested for other retroviruses (Ghez et al., 2006; Jones et al.,
2005; Pinon et al., 2003).
While receptor distribution does not explain XMRV restriction in
vivo, promoter activity displays a preference for cells of the prostate
compartment including stromal ﬁbroblasts and established cancer cell
lines LNCaP and DU145. In comparison to other investigated human
cell lines, XMRV promoter activity shows up to 10-fold higher activity
in stromal ﬁbroblast and up to 30-fold increased activity in the
prostate cancer cell line LNCaP, while the prostate cancer cell line
DU145 displayed just a marginal increase when compared to HeLa
and 293T cells. LNCaP, DU145 and prostatic stromal ﬁbroblast do grow
with similar proliferation rates while HeLa and 293T cells both process
signiﬁcantly higher proliferation rates. Increased LTR activity in
prostate epithelium and prostate stromal ﬁbroblasts is not unique to
XMRV, as other related gammaretroviral promoters (i.e., Mo-MLV and
SFFV) showed similar transcriptional activity: All cell lines tested
demonstrated similar luciferase activity, with the exception of 293T
cells, in which XMRV promoter was signiﬁcantly less active compared
to the other MLV-promoters.
Interestingly, we found efﬁcient XMRV replication (as measured
by viral RNA in dividing cells) in HeLa cells, in the prostate cancer cell
lines DU145 and LNCaP, as well as in stromal ﬁbroblasts isolated from
prostate tissue. These results are partially in line with our observation
of increased promoter activity in prostate cell lines. Interestingly,
although 293T cells possess the lowest XMRV promoter activity, they
are still capable of producing infectious viral particles–suggesting that
other aspects of the virus life cycle are relative efﬁcient in these cells.
Cells of the human rhabdomyosarcoma cell line TE671, and the
human lung cancer cell line A549 can be efﬁciently infected with
XMRV and display strong promoter activity (albeit signiﬁcantly less
than LNCaP cells), but they do not produce infectious XMRV particles;
no viral particles were observed in concentrated cell culture
supernatant nor could viral DNA be detected by PCR. These results
demonstrate that after the initial step of infection, other blocks to
XMRV infection affecting virus replication, virus integration, silencing,
assembly or release can control virus spread.
In summary, we demonstrate here that in vitro XMRV efﬁciently
infects not only prostatic stromal ﬁbroblasts or prostate epithelial
cells but also human cells of many different tissue types, as well as
cells from various animal species. A putative in vivo restriction of
XMRV infection cannot be explained by limited receptor expression
or plasma membrane localization, as demonstrated by Western Blot
analysis and binding experiments. These studies provide evidence
for signiﬁcantly higher promoter activity of gammaretroviral
promoters in cells derived from prostate tissue and are in line
with the in vivo observation of restricted XMRV infection to
prostatic stromal ﬁbroblasts as well as epithelial cells of the
prostate. It will be of great interest to understand the mechanisms
(and identify the cellular factors) by which XMRV infection/spread
is controlled in vivo.
Material and methods
Cell culture
The cells used include the human cell lines TE 671 (ATCC# CCL-
136), HeLa, 293T, the B-cell line Jijoye (ATCC #CCL-87), HL60 cells
(ATCC #CCL-240), Reh cells (ATCC #CRL-8286), prostate cancer cell
lines LNCaP (ATCC #CRL-1740) and DU145 (ATCC #HTB-81). Cell
lines from non-human species include the feral mouse cells SC-1
(ATCC#CRL-1404), murine NIH3T3 ﬁbroblasts, hamster ovary CHO
(ATCC #CCL-61), hamster A23 and BHK cells, porcine PK15 cells,
dog D17 cells, mink CCL64 cells, monkey COS7, as well as bovine
MDBK cells. Suspension cell lines, HeLa cells, HL60 cells and LNCaP
cells were grown in RPMI medium (Invitrogen) supplemented with10% FCS. All other cell lines were kept in DMEM (Invitrogen)
supplemented with 10% FCS and grown at 37 °C, 5% CO2 and 100%
relative humidity.
Stromal cell lines (PrSc) were established as described (Gerdes et
al., 1996; Tuxhorn et al., 2002). Brieﬂy, fresh tissue cores were minced
into 1-mm cubes, washed with HBSS buffer and put into 24-well
plates containing DMEM supplemented with 10% FCS, 5 μg/ml of
insulin and 0.5 μg/ml of testosterone. The explants were incubated at
37 °C, 5% CO2 and 100% relative humidity. Mediumwas changed every
48 h. Stromal cells migrated out of the tissue and attached to the
culture dish. Standard immunocytochemistry procedures were used
to evaluate the cell phenotype. Cytokeratin expression was negative
with the Santa Cruz pan-cytokeratin Ab sc-8018 and all cell lines were
100% vimentin positive (sc-7557, Santa Cruz Biotechnology). HUVEC
cells were maintained in endothelial cell basal medium (Cambrex,
Bioscience) supplemented with 10% FCS and EGM Single Quots
(Cambrex Bioscience). Only cells maintained for 5 to 10 passageswere
used in experiments.
Cells transiently expressing the XPR1 receptor were generated
by calcium phosphate-mediated transfection of receptor expression
constructs, pcDNA3.1-hXPR1 (Yang et al., 1999). 24 h post trans-
fection cells were trypsinized and seeded at 1:10 dilution into
medium containing G418 and selected for 7–10 days. Stable hXPR1
expressing cell lines were generated by single-cell clone selection.
Brieﬂy, serial tenfold dilution of transfected cells was seeded into
96-well plates 10 days after transfection. Colonies in individual
wells of plates in which approximately 20% of the total wells
showed outgrowth after 2 weeks were considered to have arisen
from a single cell clone.Plasmids
Env sequences from XMRV VP62 (GenBank: DQ399707) were
obtained by PCR using primers with BamHI restriction sites (Env 5′
BamHI 5-GGATCCATGGAAAGTCCAGCGTTCTC-3 and Env 3′ BamHI 5-
GGATCCGTAGCTAGCGTGCTAAGCC-3′) and XMRV clone A0H4 (Uris-
man et al., 2006) as template. PCR fragments were temporarily cloned
into pCR2.1 by TA cloning technique (Invitrogen), excised using
BamHI and ligated into the expression construct pHCMV (Yee et al.,
1994). The resulting plasmid, pHCMV-env VP62 was conﬁrmed by
sequencing. Plasmid pCSI-ENZB expressing the env protein of the
xenotropic NZB MLV has been described before (Battini et al., 1999).
Expression constructs encoding for 10A1 env protein (pHCMV-
10A1env) was constructed by PCR ampliﬁcation using pRR151 (Ott
et al., 1990) as template and insertion of the PCR fragment in BamHI
sites of pHCMV. Ecotropic MLV (env protein pEnv-IRES-puro) was
used as an additional control (Miller and Chen, 1996; Morita et al.,
2000). Plasmids used in pseudotyping experiments pSF91-I-eGFP-PRE
and pSV-MoMLVGag-pol have been published earlier (Beyer et al.,
2002; Schwieger et al., 2002).
LTR sequences from XMRV VP62, spleen focus forming virus
(SFFV) andMoloneyMLVwere ampliﬁed by PCR using a proof reading
taq enzyme (Platinum PfxDNA Polymerase Invitrogen), the upstream
primer U3_LTR_XhoI (5′-GCTCGAGGTAACGCCATTTTGC-3′) and the
downstream primer U5_LTR_HindIII (5′-GCAAGCTTAATGAAA-
GACCCCC-3′) Plasmids serving as PCR templates were pSF1 (GenBank
accession number AJ224005) containing the 0.58-kbp LTR of spleen-
focus forming virus and pBMN-Z-IN (Addgene plasmid 1735)
containing the 0.62 kbp moloney MLV-LTR sequences. All PCR
fragments were cloned into the ﬁreﬂy luciferase reporter plasmid
pGL4.10 [luc2] (Promega) and subsequently sequenced.
XMRV proviral clone was constructed fusing two overlapping
fragments VP62 AM-2-9 and VP62 AO-H-4, which have been
described earlier (Dong et al., 2007; Urisman et al., 2006), pCR.2.1
TOPO (Invitrogen) was used as vector backbone.
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A pCSI expression vector (Battini et al., 1999) containing the
receptor binding domain of XMRV env (aa 1-283) up to the proline
rich region (PRR) and fused to a rFc at its carboxy terminus has been
kindly provided to us by JL Battini and M Sitbon (IGMM-CNRS,
Montpellier). Recombinant protein was produced by transfecting 293
cells and harvesting the XMRVRBDrFc containing supernatant 48
h after transfection. The supernatant was ﬁltered (0.45 μm) and stored
at −80 °C. Protein expression was conﬁrmed by Western blotting.
Immunoblotting and antibodies
25 μg of total protein was analyzed by SDS PAGE and immuno-
blotted using polyclonal rabbit antisera against XPR1 (Abcam). Equal
amounts of protein loaded in cell lysate immunoblotting experiments
were veriﬁed by incubation with anti-β-tubulin Ab (Santa Cruz) or
actin Ab 1501 (Chemicon). Concentrated supernatant from the
hybridoma cells CRL-1912 (ATCC) was used to detect p30-Gag by
immunoblotting experiments.
Transient production of retrovirus vector pseudotypes and
infection protocol
Replication incompetent Env pseudotyped retroviral particles
were produced by transient transfection of phoenix cells (provided
by the Nolan lab, Stanford University, CA). 5 × 106 cells were seeded in
10-cm dish 12 h pre transfection. Culture medium was replaced
shortly before transfectionwith DMEM/FCS. 5 μg of pSF91-I-eGFP-PRE
(Schwieger et al., 2002), 10 μg of pSV-Mo-MLVgagpol (Beyer et al.,
2002) and 5 μg of the Env expressing construct were transfected using
CaPO4-HBS technique according to manufacturer's instructions
(Profection mammalian transfection system, Promega). Medium
was changed 6 h after transfectionwith 6ml of DMEM/FCS containing
20mMHEPES. Supernatant was collected every 12 h. Supernatant was
passaged through a 0.2-μm pore size ﬁlter, aliquoted and frozen at
−80 °C.
All viral supernatants were titered on TE 671 or SC-1 cells to
determine the MOI (multiplicity of infection) as described previously
(Beyer et al., 2002). Brieﬂy, 5 × 104 cells seeded in 24-well plate 4
h pre infection were incubated with the viral supernatant in the
presence of 8 μg/ml of polybrene and centrifuged at 800 × g at 37 °C
for 1 h. Medium changewas performed 1 day later and retroviral titers
were determined by ﬂow cytometry 3 days post infection and
expressed as GFP iU/ml.
Infection using replication competent XMRV
XMRV proviral DNA was transfected into LNCaP cells or 293T cells
to produce virus containing supernatant as described earlier (Dong et
al., 2007). Cells seeded in 12-well or 24-well plates were infected with
XMRV containing supernatant in the presence of polybrene. Poly-
brene containing virus-supernatant was removed 4 h after infection
and replaced by fresh medium. Cells were subsequently cultured and
successful infection was monitored by RT-PCR as well as Western
blotting for viral proteins.
Binding assay
The pCSI-XMRV-RBD-rFc construct was transiently expressed in
293T cells; 72 h after transfection culture supernatant containing the
recombinant XMRVRBDrFc protein was collected, ﬁltrated and used in
binding experiments. Target cells were washed in PBS without
Ca2+and Mg2+, detached using PBS/EDTA and washed again with
PBS containing 2% FCS. 5 × 105 cells were incubated 30 min at 37 °C
with 500 μl of culture medium containing XMRVRBDrFc. Cells werewashed multiple times with PBS containing 2% FCS and incubated
with an anti-rabbit-FITC antibody (Santa Cruz) for 30 min at 37 °C.
Cells were analyzed by ﬂow cytometry.
Transient transfections and luciferase assay
250 ng of plasmid DNA (200 ng of reporter plasmid containing the
ﬁreﬂy luciferase gene and 50 ng of renilla luciferase plasmid (pBIND-
Renilla, Promega) was transiently transfected in 5 × 104 293 cells in 6-
well plates according to manufactory instructions (ProFection
mammalian transfection system, Promega). Cells were lysed 24
h after transfection and luciferase activity was determined using the
dual luciferase reporter assay system (Promega E1960) and the
Inﬁnite M200 microplate reader (Tecan). Activity of the LTR reporter
construct was calculated as the percentage activity relative to a
plasmid containing the widely active herpes simplex virus TK
promoter in front of the ﬁreﬂy luciferase gene, pGL4 [luc2/TK]
(Promega).
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